A Phase 3 Randomized Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: MelanomaMucosal Melanoma
-
Age: Between 18 years - 100 years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1) All participants must have been diagnosed with either Stage IIIA (> 1 mm tumor in lymph node)/B/C/D or Stage IV melanoma by AJCC v8 and have histologically confirmed melanoma that is completely surgically resected (free of disease) with negative margins. 2) Central nervous system (CNS) metastases have been resected and participants are neurologically stable. 3) Prior resected CNS metastases must be without evidence of recurrence.
You may not be eligible for this study if the following are true:
-
1) History of uveal melanoma. 2) Untreated/unresected CNS metastases or leptomeningeal metastases. 3) Participants with an active, known or suspected autoimmune disease. 4) Participants with serious or uncontrolled medical disorder.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
